Portal de Periódicos da CAPES

Neurobiological aspects of the chronic fatigue syndrome

1994; Wiley; Volume: 24; Issue: 2 Linguagem: Inglês

10.1111/j.1365-2362.1994.tb00971.x

1365-2362

Jenny Bearn, Simon Wessely,

Musculoskeletal pain and rehabilitation

European Journal of Clinical InvestigationVolume 24, Issue 2 p. 79-90 Neurobiological aspects of the chronic fatigue syndrome J. BEARN, J. BEARN *Bethlem Royal and Maudsley Hospitals, LondonSearch for more papers by this authorS. WESSELY, Corresponding Author S. WESSELY †King's College School of Medicine and Dentistry, Denmark Hill and Institute of Psychiatry, London, UK2 Department of Psychological Medicine, King's College School of Medicine and Dentistry, Denmark Hill, London SE5 8AZ, UK.Search for more papers by this author J. BEARN, J. BEARN *Bethlem Royal and Maudsley Hospitals, LondonSearch for more papers by this authorS. WESSELY, Corresponding Author S. WESSELY †King's College School of Medicine and Dentistry, Denmark Hill and Institute of Psychiatry, London, UK2 Department of Psychological Medicine, King's College School of Medicine and Dentistry, Denmark Hill, London SE5 8AZ, UK.Search for more papers by this author First published: February 1994 https://doi.org/10.1111/j.1365-2362.1994.tb00971.xCitations: 35AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Byrne E. Idiopathic Chronic fatigue and myalgia syndrome (myalgic encephalomyelitis). Some thoughts on nomenclature and aetiology. Med J Aus 1988; 148: 80–2. 2 Kleinman A, Straus S. Chronic fatigue syndrome. Wiley, Chichester . CIBA Foundation Symposium 173: 1993. 3 David A. Postviral fatigue syndrome and psychiatry. Br Med Bull 1991; 47: 966–88. 4 Klonoff D. Chronic fatigue syndrome. Clin Infect Dis 1992; 15: 812–23. 5 Buchwald D, Komaroff A. Review of laboratory findings for patients with chronic fatigue syndrome. Rev Infect Dis 1991; 13 (Suppl 1): 12–18. 6 Gantz N, Holmes G. Treatment of patients with chronic fatigue syndrome. Drugs 1989; 38: 855–62. 7 Sharpe M. Psychiatric management of PVFS. Br Med Bull 1991; 47: 989–1005. 8 Wessely S. History of the postviral fatigue syndrome. Br Med Bull 1991; 47: 919–41. 9 Clements G. Survey of diagnosis of chronic fatigue. Communicable diseases and environmental health in scotland: Weekly Report: 1991; 25: 4. 10 David A, Wessely S, Pelosi A. Post-viral fatigue: time for a new approach. Br Med J 1988; 296: 696–9. 11 Holmes G, Kaplan J, Gantz N et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108: 387–9. 12 Schluederberg A, Straus S, Peterson P et al. Chronic fatigue syndrome research: definition and medical outcome assessment. Ann Intern Med 1992; 117: 325–31. 13 Sharpe M, Archard L, Banatvala J et al. Chronic fatigue syndrome: guidelines for research. J Roy Soc Med 1991; 84: 118–21. 14 Wessely S. Old Wine in New Bottles: Neurasthenia and “ME”. Psychol Med 1990; 20: 35–53. 15 Young P. Two cases of neurasthenia of long standing successfully treated by the Weir Mitchell Method. Edin Clin Path J 1884; 1: 905–9. 16 Robertson W. The infective factors in some types of neurasthenia. J Ment Sci 1919; 65: 16–24. 17 Dicks H. Neurasthenia: Toxic and Traumatic. Lancet 1933; ii: 683–6. 18 Lane C. The mental element in the etiology of neurasthenia. J Nerv Ment Dis 1906; 33: 463–6. 19 Imboden J, Canter A, Cluff L. Brucellosis. III. Psychologic aspects of delayed convalescence. Arch Intern Med 1959; 103: 406–14. 20 DeFreitas E, Hilliard B, Cheney P et al. Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci 1991; 88: 2922–6. 21 Gow J, Simpson K, Schliephake A et al. Search for retrovirus in the chronic fatigue syndrome. J Clin Pathol 1992; 45: 1058–61. 22 Anon. Inability of retroviral tests to identify persons with chronic fatigue syndrome, 1992. MMWR 1993; 42: 93–4. 23 Khan A, Heneine W, Chapman L et al. Assessment of a retrovirus sequence and other possible risk factors for the chronic fatigue syndrome in adults. Ann Int Med 1993; 118: 241–5. 24 Hellinger W, Smith T, van Scoy R, Spitzer P, Forgacs P, Edson R. Chronic fatigue syndrome and the diagnostic utility of Epstein-Barr Virus early antigen. J Am Med Assoc 1988; 260: 971–3. 25 Straus S. The Chronic Mononucleosis Syndrome. J Infect Dis 1988; 157: 405–12. 26 White P. Psychiatric Illness following Glandular Fever. Abstracts of the Annual Meeting of the Royal College of Psychiatrists. Brighton, April 5th 1991. 27 Yousef G, Bell E, Mann G et al. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet i; 1988: 146–50. 28 Archard L, Bowles N, Behan P, Bell E, Doyle D. Postviral fatigue syndrome: persistence of enterovirus in muscle and elevated creatine kinase. J Roy Soc Med 1988; 81: 326–9. 29 Gow J, Behan W, Clements G, Woodall C, Riding M, Behan P. Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome. Br Med J 1991; 302: 692–6. 30 Wessely S. Viruses and fatigue: the current status of the chronic fatigue syndrome. In: E. Kurstak, ed Psychiatry and Biological Factors. New York : Plenum, 1991: 231–56. 31 McCartney R, Banatvala J, Bell E. Routine use of mu-antibody capture ELISA for the serological diagnosis of Coxsackie B Virus infections. J Medical Virology 1986; 19: 205–212. 32 Miller N, Carmichael H, Calder B et al. Antibody to coxsackie B virus in diagnosing postviral fatigue syndrome. Br Med J 1991; 302: 140–3. 33 Milton J, Clements G, Edwards R. Immune responsiveness in chronic fatigue syndrome. Postgrad Med J 1991; 67: 532–7. 34 Lynch S, Seth R. Postviral fatigue syndrome and the VP-I antigen. Lancet 1989; ii: 1160–1. 35 Halpin D, Wessely S. VP-1 antigen in chronic postviral fatigue syndrome. Lancet 1989; i: 1028–9. 36 de la Torre J, Borrow P, Oldstone M. Viral persistence and disease: Cytopathology in the absence of cytolysis. Br Med Bull 1991; 47: 838–51. 37 Behan P, Behan W. The Postviral Fatigue Syndrome. CRC Critical Reviews in Neurobiology 1988; 42: 157–78. 38 Behan W, More I, Behan P. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991; 83: 61–5. 39 Jamal G, Hansen S. Post-viral fatigue syndrome: evidence for underlying organic disturbance in the muscle fibre. Eur Neurol 1989; 29: 273–6. 40 Barnes P, Taylor D, Kemp G, Radda G. Skeletal muscle bioenergetics in the chronic fatigue syndrome. J Neurol Neurosurg Psychiat 1993; 56: 679–83. 41 Edwards R, Newham D, Peters T. Muscle biochemistry and pathophysiology in postviral fatigue syndrome. Br Med Bull 1991; 47: 826–37. 42 Teahon K, Preddy V, Smith D, Peters T. Clinical Studies of the post-viral fatigue syndrome (PVFS) with special reference to skeletal muscle function. Clin Sci 1988; 75: 45P. 43 Wagenmakers A, Coakley J, Edwards R. Metabolic consequences of reduced habitual activities in patients with muscle pain and disease. Ergonomics 1988; 31: 1519–27. 44 Asher R. The dangers of going to bed. Br Med J 1947; 4: 976–8. 45 Stokes M, Cooper R, Edwards R. Normal strength and fatigability in patients with effort syndrome. Br Med J 1988; 297: 1014–18. 46 Riley M, O'Brien C, McCluskey D, Bell N, Nicholls D. Aerobic work capacity in patients with chronic fatigue syndrome. Br Med J 1990; 301: 953–6. 47 Lloyd A, Gandevia S, Hales J. Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome. Brain 1991; 114: 85–98. 48 Kent-Braun J, Sharma K, Chein C, Weiner M, Miller R. Chronic fatigue syndrome: pathophysiologic basis for muscular fatigue. Neurology 1993; 43: 125–31. 49 Rutherford O, White P. Human quadriceps strength and fatigability in patients with post-viral fatigue. J Neurol Neurosurg Psychiat 1991; 54: 961–4. 50 Lloyd A, Hales J, Gandevia S. Muscle strength, endurance and recovery in the post-infection fatigue syndrome. J Neurol Neurosurg Psychiat 1988; 51: 1316–22. 51 Gibson H, Carroll N, Clague J, Edwards R. Exercise performance and fatiguability in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiat 1993; 156: 993–8. 52 Wessely S, Powell R. Fatigue Syndromes: A Comparison of Chronic “postviral” Fatigue with Neuromuscular and Affective Disorders. J Neurology, Neurosurg Psychiat 1989; 42: 940–8. 53 Wood G, Bentall R, Gopfert M, Edwards R. A comparative psychiatric assessment of patients with chronic fatigue syndrome and muscle disease. Psychol Med 1991; 21: 619–28. 54 Blakely A, Howard R, Sosich R, Murdoch J, Menkes D, Spears G. Psychological symptoms, personality and ways of coping in chronic fatigue syndrome. Psychol Med 1991; 21: 347–62. 55 Millon C, Salvato F, Blancy N et al. A psychological assessment of chronic fatigue syndrome/chronic Epstein Barr virus patients. Psychol Health 1989; 3: 131–41. 56 Katon W, Russo J. Chronic fatigue syndrome criteria: a critique of the requirement for multiple physical complaints. Arch Intern Med 1992; 152: 1604–9. 57 Lewis G, Wessely S. The epidemiology of fatigue: more questions than answers. J Epidemiol Comm Health 1992; 46: 92–7. 58 Wessely S. The neuropsychiatry of chronic fatigue syndrome. In: S Straus, A Kleinman ed. Chronic Fatigue Syndrome. Chichester : CIBA Foundation Symposium 173, John Wiley, 1993: 212–237. 59 Smith A. Cognitive changes in myalgic encephalomyelitis. In: R Jenkins, J Mowbray eds. Post-viral Fatigue Syndrome. Chichester : Wiley, 1991: 179–204. 60 Grafman J, Schwartz V, Dale J, Scheffers M, Houser C, Straus S. Analysis of Neuropsychological Functioning in Patients with Chronic Fatigue Syndrome. J Neurol, Neurosurg Psychiat 1993; 56: 684–9. 61 Riccio M, Thompson C, Wilson B, Morgan R, Lant A. Neuropsychological and psychiatric abnormalities in myalgic encephalomyelitis: A preliminary report. Br J Med Psychol 1992; 31: 111–20. 62 DeLuca J, Johnson S, Natelson B. Information processing efficiency in chronic fatigue syndrome and multiple sclerosis. Arch Neurol 1993; 50: 301–4. 63 Altay H, Abbey D, Toner B, Salit I, Brooker H, Garfinkel P. The neuropsychological dimensions of postinfectious neuromyasthenia (chronic fatigue syndrome): a preliminary report. Int J Psychiat Med 1990; 20: 141–9. 64 Millon C, Salvato F, Blaney N et al. A psychological assessment of chronic fatigue syndrome/chronic Epstein Barr virus patients. Psychol Health 1989; 3: 131–41. 65 Sandman C, Barron J, Nackoul K, Goldstein J, Fidler F. Memory deficits associated with chronic fatigue immune dysfunction syndrome. Biol Psychiat 1993; 33: 618–23. 66 McDonald E, Cope H, David A. Neuropsychological performance in a primary care study sample of chronically fatigued patients. J Neurol Neurosurg Psychiat 1993; 56: 812–15. 67 Robbins T, Joyce E, Sahakian B. Neuropsychology and imaging. In: E Paykel ed. Handbook of Affective Disorders. Edinburgh : Churchill Livingstone, 1992: 289–308. 68 Cohen R, Weingartner H, Smallberg S, Pickar D, Murphy D. Effort and cognition in depression. Arch Gen Psychiat 1982; 39: 593–7. 69 Buchwald D, Cheney PR, Peterson DL et al. A chronic illness characterised by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992; 116: 103–13. 70 Mena I. Abstracts of the Cambridge Symposium on Myalgic Encephalomyelitis. Nightingale 1990; 1: 21–22. 71 Costa D, Brostoff J, Douli V, Ell P. Postviral fatigue syndrome. Br Med J 1992; 304: 1567. 72 Ichise M, Salit I, Abbey S, Chung D, Gray B, Kirsh J, Freedman M. Technetium-99m HM-PAO photon emission computed tomography (SPECT) in the chronic fatigue syndrome. Nucl Med Commun 1992; 13: 767–72. 73 Prasher D, Smith A, Findley L Sensory and cognitive event-related potentials in myalgic encephalomyelitis. J Neurol Neurosurg Psychiat 1990; 53: 247–53. 74 Scheffers M, Johnson R, Grafman J, Dale J, Straus S. Attention and short-term memory in chronic fatigue syndrome patients: an event-related potential analysis. Neurology 1992; 42: 1667–75. 75 Demitrack M, Dale J, Straus S et al. Evidence for impaired activation of the hypothalamic-pituitary adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrin Metab 1991; 73: 1224–34. 76 Sachar E, Hellman M, Roffwarg H, Halpern F, Fukushima D, Gallagher T. Disrupted 24 hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiat 1973; 28: 19–24. 77 Carroll B. Limbic system-adrenal cortex regulation in depression and schizophrenia. Psychosomatic Med 1976; 38: 106–21. 78 Carroll B, Curtis G, Mendels J. Cerebrospinal fluid and plasma free cortisol concentrations in depression. Psychol Med 1976; 6: 235–44. 79 Linkowski P, Mendlewicz J, Leclerq R, et al. The 24 hour profile of adrenocorticotrophin and cortisol in major depressive illness. J Clin Endocrinol Metab 1985; 61: 429–38. 80 Charlion B, Leake A, Wright C, Griffiths H, Ferrier I. A combined study of cortisol, ACTH and dexamethasone concentrations in major depression: multiple timepoint sampling. Br J Psychiat 1987; 150: 791–6. 81 Gold P, Loriaux D, Roy A et al. Responses to corticotrophin-releasing hormone in the hypercortisolism of depression and Cushing's disease: pathophysiologic and diagnostic implications. N Engl J Med 1986; 314: 1329–35. 82 Amsterdam J, Winokur A, Abelman E, Lucki I, Riokel K. Cosynotropin (ACTH 1–24) stimulation test in depressed patients and healthy subjects. Am J Psychiat 1983; 104: 907–9. 83 Jaeckle R, Kathol R, Lopez J, Meller W, Krummel S. Enhanced adrenal sensitivity to exogenous cosynotropin (ACTH 1–24) stimulation in major depression. Arch Gen Psychiatry 1987; 44: 233–40. 84 Gold P, Crousos G, Kellner C et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiat 1984; 141: 619–27. 85 Holsboer F, Gerken A, von Bradelbeau U et al. Human corticotropin-releasing hormone in depression: correlation with thyrotropin secretion following thyrotropin-releasing hormone. Biol Psychiat 1986; 21: 601–11. 86 Amsterdam J, Marinelli D, Arger P, Winokur A. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. Psychiat Res 1987; 21: 189–97. 87 Dorovini-Ziz K, Ziz A. Increased adrenal weight in victims of violent suicide. Am J Psychiat 1987; 144: 1214–5. 88 Charlton B, Ferrier I. Hypothalamo-pituitary adrenal axis abnormalities in depression: a review and a model. Psychol Med 1989; 19: 331–6. 89 Schulte H, Chrousos G, Gold P et al. Continuous administration of synthetic ovine CRF in man. J Clin Invest 1985; 75: 1781–5. 90 Lisansky J, Peake G, Strassman J et al. Augmented pituitary corticotropin response to human CRF in depressives pretreated with metyrapone. Arch Gen Psychiat 1989; 46: 641–3. 91 Banki C, Bissette G, Arato M, O'Connor L, Nemeroff C. Cerebrospinal fluid corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiat 1987; 144: 873–7. 92 Nemeroff C, Bissette G, Akil H, Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiat 1991; 158: 59–63. 93 Nemeroff C. The role of corticotrophin-releasing factor in the pathogenesis of major depression. Pharmacopsychiat 1988; 21: 76–82. 94 Crompton M, Ferrier I. Corticotropin-releasing factor immunoreactivity in post-mortem brains from depressed suicides. J Psychopharmacol 1988; 2: 13–18. 95 Britton K, Koob G. Behavioural effects of corticotropin-releasing factor. In: A Schatzberg, C Nemeroff, eds The Hypothalamic Pituitary Adrenal Axis New York : Raven Press, 1988: 60–83. 96 Gold P, Goodwin P, Chrousos G. Clinical and biochemical manifestations of depression. Relationship to the neurobiology of stress. New Engl J Med 1988; 319: 348–53; 413–20. 97 Checkley S. Neuroendocrine mechanisms and the precipitation of depression by life events. Br J Psychiat 1992; 160(suppl 15): 7–17. 98 Veldhuis H, de Korte C, de Kloet E. Glucocorticoids facilitate the retention of acquired immobility during forced swimming. Eur J Pharmacol 1985; 115: 211–17. 99 Griep E, Boersman J, de Kloet E. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993; 20: 469–74. 100 Yehuda R, Southwick S, Nussbaum G, Wahby V, Giller E, Mason J. Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis 1990; 176: 366–9. 101 Joseph-Vanderpool J, Rosenthal N, Chrousos G et al. Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. J Clin Endocrinol Metab 1991; 72: 1382–7. 102 Liposits Z, Phelix C, Paull W. Synaptic interaction of serotonergic axons and corticotrophin-releasing factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. Histochemistry 1987; 86: 541–9. 103 Delbende C, Delarue C, Lefebure H et al. Glucocorticoids, transmitters and stress. Br J Psychiatry 1992; 160(suppl 15): 24–34. 104 Gibbs D, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotrophin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res 1983; 280: 176–9. 105 Gartside S, Cowen P. Mediation of ACTH and prolactin responses to 5-HTP by 5HT2 receptors. Eur J Pharmacol 1990; 179: 103–9. 106 Coccaro E, Gabniel S, Siever L. Buspirone challenge: preliminary evidence for a role for central 5HT1a a receptor function in impulsive aggressive behaviour in humans. Psychopharm Bull 1990; 26: 393–405. 107 Bearn J, Raven P. Neuroendocrine development in psychiatric research. In: R Kerwin, D Dawbarn, J McCulloch, C Tamminga eds. Cambridge Medical Reviews: Neurobiology and Psychiatry Vol 2 Cambridge : Cambridge University Press 1993: in press. 108 Bakheit AMO, Behan PO, Dinan TG, Gray CE, O'Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Br Med J 1992; 304: 1010–12. 109 Perowtka S. Selective interaction of novel anxiolytics with 5HT1a receptors. Biol Psychiat 1985; 20: 971–9. 110 Meltzer H, Lee H, Nash J. Effects of buspirone on prolactin secretion is not mediated by 5HT1a receptor stimulation. Arch Gen Psychiat 1992; 42: 163. 111 Garatini S, Mennini T, Samanin R. From fenfluramine racemate to d-fenfluramine: specificity and potency of the effects on the serotonergic system and food intake. Ann NY Acad Sci 1987; 499: 156–66. 112 O'Keane V, Dinan T. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiat 1991; 148: 1009–15. 113 Bearn J, Allain T, Coskaran P, Butler J, McGregor A, Wessely S. Neuroendocrine responses to d-fenfluramine and insulin induced hypoglycaemia in chronic fatigue syndrome. Submitted. 114 Demitrack M, Gold P, Dale J, Krahn D, Kling M, Straus S. Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol Psychiat 1992; 32: 1065–77. 115 Ameisen J-C, Meade R, Askenase P. A new interpretation of the involvement of serotonin in delayed-type hypersensitivity. J Immunol 1989; 142: 3171–9. 116 Straus S, Dale J, Wright R, Metcalfe D. Allergy and the chronic fatigue syndrome. J Allergy Clin Immunol 1988; 81: 791–5. 117 Barnes R, Veith R, Borson S et al. High levels of plasma catecholamines in dexamethasone-resistant depressed patients. Am J Psychiat 1983; 140: 1623–5. 118 Koslow J, Maas J, Bowden C, Davis J, Hanin I, Javaid J. CSF and urinary biogenic amines and metabolites in depression and mania: a controlled, univariate analysis. Arch Gen Psychiat 1983; 40: 999–1010. 119 Mitchell P, Bearn J, Corn T, Checkley S. Growth hormone responses to clonidine after recovery in patients with endogenous depression. Br J Psychiat 1988; 152: 34–8. 120 Serri O, Rasio E, Somma M. Effects of naloxone on insulin-induced release of pituitary hormones. J Clin Endocrinol Metab 1981; 53: 206–8. 121 Cuneo R, Livesey J, Nicholls M, Espiner E, Donald R. Effects of alpha-1 adrenergic blockade on the hormonal response to hypoglycaemic stress in normal man. Clin Endocrinol 1987; 26: 1–8. 122 Tomori N, Suda T, Nakagami Y et al. Adrenergic modulation of adrenocorticotropin responses to insulin-induced hypoglycaemia and corticotropin-releasing hormone. J Clin Endocrinol Metab 1989; 68: 87–93. 123 Cavagnini F, Raggi U, Micossi P, Di Landro A, Invitti C. Effect of an antiserotonergic drug, metergoline on the ACTH and cortisol response to insulin hypoglycaemia and lysine-vasopressin in man. J Clin End Metab 1976; 43: 306–12. 124 Evans P, Dieguez C, Rees L, Hall R, Scanlon M. Effect of cholinergic blockade on the ACTH, β-endorphin and cortisol responses to insulin-induced hypoglycaemia. Clin Endocrinol 1986; 24: 687–91. 125 Fish H, Chernow B, O'Brian J. Endocrine and neurophysiologic responses of the pituitary to insulin-induced hypoglycaemia: a review. Metabolism 1986; 35: 763–80. 126 Bennett R, Clark S, Campbell S, Burckhardt C. Low levels of somatomedin C in patients with the fibromyalgia syndrome. Arthritis Rheum 1992; 35: 1113–16. 127 Sachar E, Finkelstein J, Hellman L. Growth hormone responses in depressive illness. 1. Response to insulin tolerance test. Arch Gen Psychiat 1971; 25: 263–9. 128 Brunswick D, Frazer A, Koslow S et al. Insulin-induced hypoglycaemic response and release of growth hormone in depressed patients and healthy controls. Psychol Med 1988; 18: 79–91. 129 Griep E, Boersma J, de Kloet E. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993; 20: 469–74. 130 Kent S, Bluthe R-M, Kelley K, Dantzer R. Sickness behaviour as a new target for drug development. Trends Pharmaceut Sci 1992; 13: 24–8. 131 MacDonald L, Mann A, Thomas H. Interferons and mediators of psychiatric morbidity: an investigation in a trial of recombinant alpha interferon in hepatitis B carriers. Lancet ii; 1175–8. 132 McDonald E, Mann A. Interferon in Viral Illness and Myalgic Encephalomyelitis. In: R Jenkins, J Mowbray Eds. Postviral Fatigue Syndrome Chichester : John Wiley, 1991: 195–204. 133 Tsagarakis S, Gillies G, Rees L, Besser M, Grossman A. Interleukin-1 directly stimulates the release of corticotrophin releasing factor from rat hypothalamus. Neuroendocrinol 1989; 49: 98–101. 134 Shoham S, Davenne D, Cady A, Dinarello C, Krueger J. Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol 1987; 253: R142–9. 135 Ur E, White P, Grossman A. Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur Arch Psychiatry Clin Neurosci 1992; 241: 317–22. 136 Lloyd A, Hickie I, Brockman A, Dwyer J, Wakefield D. Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome and control subjects. J Infection 1991; 164: 1023–4. 137 Besedovsky H, del Rey A, Sorkin E, Dinarello C. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986; 233: 653–4. 138 Baybutt H, Holsboer F Inhibition of macrophage differentiation and function by cortisol. Endocrinology 1990; 127: 476–80. 139 Fauci A. Immunosuppressive and anti-inflammatory effects of glucocorticoids. In: J Baxter, G Rousseau eds. Glucocorticoid Hormone Action. New York : Springer, 1979: 449–65. 140 Landay A, Jessop C, Lennette E, Levy J. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338: 707–12. 141 Buchwald D, Komaroff A. Review of laboratory findings for patients with chronic fatigue syndrome. Rev Infect Dis 1991; 13 (Suppl 1): 12–18. 142 Lutgendorf S, Brickman A, Antoni M et al. Immune functioning predicts cognitive difficulties in chronic fatigue syndrome. Psychosom Med 1993; 55: 100. 143 Antoni M, Brickman A, Imia-Fins A et al. Cognitive appraisals and coping strategies predict chronic fatigue syndrome disturbances (Abstract). In: Proceedings of the International CFS/ME Research Conference. Albany, New York , Oct 34, 1992. 144 Maes M, Jacobs J, Lambreckhts J. Evidence for a systemic immune activation during depression: results of leucocyte enumberation by flow cytometry in conjunction with antibody staining. Psychol Med 1992; 22: 45–53. 145 Imboden J. Psychosocial determinants of recovery. Adv Psychosom Med 1972; 8: 142–55. 146 Stone R. Presentation, Investigation and Diagnosis of PVFS (ME) in General Practice. In: R Jenkins, J Mowbray, Eds. Postviral Fatigue Syndrome. Chichester : John Wiley, 1991: 221–6. 147 Harding T, de Arango M, Baltazar J et al. Mental disorders in primary health care: a study of their frequency and diagnosis in four developing countries. Psychol Med 1980; 10: 231–41. 148 Wilson D, Widmer R, Cadoret R, Judiesch K. Somatic symptoms: a major feature of depression in a family practice. J Affective Disord 1983; 5: 199–207. 149 Goodnick P, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiat 1993; 54: 13–20. 150 Lane T, Matthews D, Manu P. The low yield of physical examinations and laboratory investigations of patients with chronic fatigue. Am J Med Sci 1990; 299: 313–18. 151 Valdini A, Steinhardt S, Feldman E. Usefulness of a standard battery of laboratory tests in investigating chronic fatigue in adults. Fam Pract 1989; 6: 286–91. 152 Armon C, Kurland L. Chromic fatigue syndrome: issues in the diagnosis and estimation of incidence. Rev Infect Dis 1991; 13(Suppl 13): 68–72. Citing Literature Volume24, Issue2February 1994Pages 79-90 ReferencesRelatedInformation